How I Invest with David Weisburd
How I Invest with David Weisburd is a podcast that interviews the world's leading institutional investors. Previous guests include The Ford Foundation, Northwestern University Endowment, CalPERS, Stepstone, and other top limited partners.
E25: Jeff Galvin, CEO of Addimmune on Finding a Cure for HIV
Jeff Galvin, CEO of Addimmune, sits down with David Weisburd to discuss cell and gene therapy, and how Addimmune is working on a functional solution for HIV. We’re proudly sponsored by Bidav Insurance Group, visit lux-str.com if you’re ready to level up your insurance plans.
Key Points
- In phase 1 trials, AGT 103-T showed no serious adverse events and indicated potential efficacy through blood markers, demonstrating safety and a positive response in HIV patients who remained on antiretrovirals.
- The anti-retroviral withdrawal study with AGT 103-T revealed that treated patients maintained stable CD4 counts and had an increase in CD8 cells, suggesting an effective immune response against HIV when antiretrovirals were stopped.
- American Gene Technologies (AGT) is working towards a public listing with the support of 10x Capital and is part of a broader gene and cell therapy revolution that aims to transition from treating to curing diseases, with around 30 approved therapies already in the market.
Chapters
| 0:00 | |
| 2:21 | |
| 5:08 | |
| 8:22 | |
| 11:53 | |
| 12:39 | |
| 16:11 | |
| 20:14 | |
| 23:22 | |
| 29:43 | |
| 30:52 |
Transcript
Loading transcript...
- / -